Rapid Diagnostic Kits Market Size (2024 - 2029)

The rapid diagnostic kits market is projected to experience significant growth, driven by increased government initiatives for diagnosing infectious diseases and rising awareness about early diagnosis. The market's expansion is further supported by advancements in technology and the development of new diagnostic assays, which have become crucial for infection tracking and surveillance programs. Although the COVID-19 pandemic initially boosted the market, the focus has shifted to other infectious and chronic diseases as infections decline. Despite these positive trends, challenges such as a lack of awareness about new rapid diagnostic tests and the continued need for traditional diagnostic methods may hinder market growth.

Market Size of Rapid Diagnostic Kits Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Rapid Diagnostic Kits Market Summary
Study Period 2021 - 2029
Market Size (2024) USD 21.35 Billion
Market Size (2029) USD 32.90 Billion
CAGR (2024 - 2029) 8.83 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Rapid Diagnostic Kits Market Analysis

The Rapid Diagnostic Kits Market size is estimated at USD 21.35 billion in 2024, and is expected to reach USD 32.90 billion by 2029, growing at a CAGR of 8.83% during the forecast period (2024-2029).

The COVID-19 pandemic positively impacted the rapid diagnostics market in terms of revenue; however, the pandemic negatively impacted the sales of routine testing kits used for non-COVID-19 diseases and lockdowns. For instance, in April 2021, the Federal Government of Germany made it mandatory for employers in Germany to offer free COVID-19 self-testing kits to employees not working from home once a week. Further, in March 2021, The German Federal Ministry of Health approved the sale of COVID-19 rapid antigen tests in supermarket chains, drug stores, pharmacies, and e-commerce websites. Additionally, in March 2021, Becker's Healthcare published that the United States government launched a national testing strategy to control the spread of COVID-19. Through this testing strategy, the Government opened four COVID-19 testing hubs nationwide with an investment of USD 650 million.

Moreover, the launches of several COVID-19 diagnostics kits and government investments in COVID-19 research further boosted the market growth during the pandemic. However, in the post-pandemic period, the number of COVID-19 infections decreased, and the research, diagnosis, and treatment of other infectious and chronic diseases resumed, leading to the market's growth. Thus, COVID-19 boosted the growth of the market initially. However, the market is growing normally with the decrease in the COVID-19 infection and the resumption of rapid diagnosis of other infectious and chronic diseases.

Furthermore, the rapid diagnostic kits market is expected to grow during the forecast period with the increasing government initiatives for diagnosing infectious diseases, rising awareness regarding early diagnosis among people, and shifts in technological and commercial environments.

In the past few years, infection tracking and surveillance programs have increased to track the infection rate of certain pathogens. These programs utilize rapid diagnostic assays to detect and confirm infections. Thus, with such programs, the demand for rapid diagnostic assays is expected to increase, likely to drive market growth. The Early and timely identification of infectious diseases propels disease surveillance programs and is important for vector control measures. Due to their easy accessibility and quick turnaround time for results, rapid test kits are increasingly being utilized to track recent emerging infections. For instance, in February 2021, the Centers for Disease Control and Prevention (CDC) reported 7,860 cases of Tuberculosis in the United States (a rate of 2.4 per 100,000 persons).

Further, in May 2021, according to the data published by the TB Facts Org 2021, over 10.6 million were estimated to be affected with Tuberculosis (TB) in the year 2021, which showed an increase of 4.5% compared to the previous year. Furthermore, while microscopy and culture remain essential for tuberculosis laboratory diagnosis, the spectrum of rapid diagnostic test kits, particularly the Nucleic Acid Amplification Test (NAAT), has greatly expanded. For instance, The World Health Organization (WHO) in 2021 recommended the use of molecular NAATs for Tuberculosis detection instead of smear microscopy since they detect Tuberculosis more correctly, especially in patients with paucibacillary illness and persons living with Human immunovirus (HIV). They are becoming more widely available for detecting and identifying mycobacterium tuberculosis complex in clinical specimens and for diagnosing multi-drug resistant strains. Further, in March 2022, Brain Chemistry Labs, a non-profit research institute, and Arlington Scientific, a Utah-based medical test kit manufacturer, announced the development of an easy-to-use rapid test kit. This kit will detect the presence of β-methylamino-L-Alanine (BMAA), a toxin in cyanobacterial blooms, which causes a fatal paralytic disease called Amyotrophic Lateral Sclerosis (ALS). Thus, with such developments, the penetration of rapid diagnostic assays is expected to increase further, driving the market's growth in the coming years.

Additionally, the increasing government initiatives for diagnosing and researching infectious diseases are boosting the growth of the studied market. For instance, in September 2021, the Government of New Zealand invested over USD 22.47 million (NZD 36 million) in a new Infectious Diseases Research Platform to support Aotearoa New Zealand's Covid-19 response and preparedness for future pandemics. Further, in September 2022, the Government of Australia invested over USD 179.02 million (AUD 266 million) for three years into the seventh replenishment of the global fund to control acquired immunodeficiency syndrome (AIDS), malaria, and Tuberculosis.

Therefore, owing to the factors above, including the increasing prevalence of infectious diseases, increasing government investment in research, and the key developments by the market players, the studied market is anticipated to witness growth over the analysis period. However, the lack of awareness regarding newer rapid diagnostic tests and failure to eliminate the need for microscopy diagnosis will likely impede market growth.

Rapid Diagnostic Kits Industry Segmentation

As per the scope of the report, rapid diagnostic kits are used for detecting or diagnosing a wide range of infections, conditions, and diseases in humans and animals also. Moreover, these kits offer accurate diagnoses for diseases, such as malaria, diabetes, and pregnancy. The Rapid Diagnostic Kits Market is Segmented by Technology (Solid Phase, Lateral Flow, Agglutination Assays, and Others), End User (Hospitals and Clinics, Homecare, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD) for the above segments.

By Technology
Solid Phase
Lateral Flow
Agglutination Assays
Other Technologies
By End User
Hospitals and Clinics
Homecare
Other End-Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Rapid Diagnostic Kits Market Size Summary

The rapid medical diagnostic kits market is poised for significant growth, driven by the increasing demand for quick and accurate disease detection. The market experienced an initial boost due to the COVID-19 pandemic, which highlighted the importance of rapid testing solutions. Government initiatives and investments in COVID-19 research and diagnostics further propelled market expansion during this period. As the pandemic's impact waned, the focus shifted back to the diagnosis of other infectious and chronic diseases, sustaining the market's growth trajectory. The market is expected to continue expanding, supported by rising awareness of early diagnosis, technological advancements, and increased government efforts to combat infectious diseases.

The market's growth is further bolstered by the expanding use of rapid diagnostic assays in infection tracking and surveillance programs, which are crucial for timely disease identification and control measures. The hospital and clinic segment is anticipated to experience substantial growth due to advanced medical infrastructure and strategic partnerships aimed at enhancing diagnostic services. North America is expected to witness significant market growth, driven by a high prevalence of chronic and infectious diseases, substantial government investments, and key developments by market players. The competitive landscape features several global and regional companies, with ongoing innovations and collaborations expected to enhance market penetration and drive future growth.

Explore More

Rapid Diagnostic Kits Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Government Initiatives for the Diagnosis of infectious Diseases

      2. 1.2.2 Rising Awareness Regarding Early Diagnosis among People

      3. 1.2.3 Shift in Technological and Commercial Environment

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness Regarding Newer Rapid Diagnostic Tests

      2. 1.3.2 Failure to Eliminate the Need for Microscopy Diagnosis

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Technology

      1. 2.1.1 Solid Phase

      2. 2.1.2 Lateral Flow

      3. 2.1.3 Agglutination Assays

      4. 2.1.4 Other Technologies

    2. 2.2 By End User

      1. 2.2.1 Hospitals and Clinics

      2. 2.2.2 Homecare

      3. 2.2.3 Other End-Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Rapid Diagnostic Kits Market Size FAQs

The Rapid Diagnostic Kits Market size is expected to reach USD 21.35 billion in 2024 and grow at a CAGR of 8.83% to reach USD 32.90 billion by 2029.

In 2024, the Rapid Diagnostic Kits Market size is expected to reach USD 21.35 billion.

Rapid Medical Diagnostic Kits Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)